Futures Pause Ahead of ADP Jobs Report 📈

[Image](www.elitetrade.club) Good Morning! Hey, there! It's Chris from Elite Trade Club, here to give you this morning's premarket trading news. It's Wednesday, April 5th. I hope you have a great day in the market. Now, let's get ready to trade! Markets 📈 Stocks slid on Tuesday after weaker-than-expected data on U.S. job opening shook investor confidence. The Dow, Nasdaq, and S&P 500 fell 0.5%, while the small-cap Russell 2K sold off for a 1.8% loss. S&P 500 futures are down 0.1% in early-morning trading. Sponsored [Uncover Huge Upside Potential with this AI-Enabled Biotech!]( 🔥 This AI-enabled biotech stock could capture significant market share in the $315 billion diagnostics market. The stock boasts a low float, keen M&A approach, roll-up synergies, AI-enhanced research, and, best of all, Insiders own over 33% of shares! This could be one of the most promising up-and-coming biotech stocks on the market. Don't miss out on this one! [Click here for the name and ticker symbol of this AI-Enabled Biotech]( Premarket Highlights 🔎 🥇 Gold Clears $2,000 Mark Gold futures rallied past $2,000 per ounce in Tuesday's trading session. It's currently trading at $2,038 in early premarket trading. The precious metal has been steadily gaining since the banking crisis kicked off a few weeks ago. Growing concerns among investors about the U.S. dollar's continued global hegemony could also be fueling the rally. What to Watch Today 👀 ADP Employment Report New data on the state of the U.S. job market drops at 8:30 a.m. in the form of the March ADP employment report. After seeing the way the market reacted to Tuesday's job openings read, I wouldn't be surprised if this report drove volatility in today's session. Median forecasts estimate the report will show 210,000 new private-sector jobs created in March, and the market could react negatively if the data misses the mark. Major Earnings 💰 Conagra Brands, Inc. [CAG] ... AM The Simply Good Foods Company [SMPL] ... AM Schnitzer Steel Industries, Inc. [SCHN] ... AM Simulations Plus, Inc. [SLP] ... PM Richardson Electronics, Ltd. [RELL] ... PM Natuzzi, S.P.A. Dr [NTZ] ... PM Seachange International, Inc. [SEAC] ... PM Economy 🏗 - ADP employment [Mar] ... 8:15a - U.S. trade balance [Feb] ... 8:30a - S&P final U.S. services PMI [Mar] ... 9:45a - ISM services [Mar] ... 10:00a Running Hot 🔥 Gainers - Kineta [KA] >> +17.6% - 180 Life Sciences [ATNF] >> +18.7% - Ricebran Tech [RIBT] >> +15.1% Decliners - Secoo Holding [SECO] >> (20.5%) - Guardforce AI [GFAI] >> (7.2%) - Deep Medicine SPAC [DMAQ] >> (10.7%) Liminal BioScience [LMNL] - Last Close: $3.62 Liminal Bio is rallying on news of a buyout proposal. Thomvest Asset Management has made a non-binding offer to acquire the biopharma firm at a proposed price of $7.50 per share. The bid represents a 107% premium to LMNL's Tuesday closing price. Thomvest currently controls 64% of Liminal Bio via a wholly-owned limited partnership called Structured Alpha LP. Liminal BioScience has yet to comment on the proposal, but shares are up 88.1% on the news. My Take: There's still some potential upside left int his trade if LMNL accepts the proposal. This one could be worth watching. InflaRx [IFRX] - Last Close: $3.77 InflaRx is running hot after a regulatory green light. The clinical-stage biotech yesterday announced on Tuesday that the FDA had awarded its Gohibic drug candidate with an Emergency Use Authorization (EUA). Drug regulators approved Gohobic, or viobelimab, as an emergency treatment for critically-ill COVID-19 patients based on data from a Phase 3 PANAMO trial. IFRX soared 83.9% on Tuesday after the news hit the market, and shares continued to push higher in the after-market. This morning, IFRX is up 16.1% ahead of the opening bell, and it's one of the premarket's most actively-traded stocks. My Take: It's pretty late in the game to try and jump in this rally. Watch out for a potential pull-back at today's opening bell. Immunic [IMUX] - Last Close: $1.46 A new bout of promising drug data is boosting shares of Immunic. The micro-cap biotech said a Phase 2b study of vidofludimus calcium in ulcerative colitis patients produced an impressive clinical remission rate. Immunic said patients receiving vidofludimus exhibited a remission rat of 61.5% at week 50, compared with a 27.8% rate for placebo. Immunic also noted that the drug produced a statistically-significant, dose-linear rise in endoscopic healing that was a 38% improvement over placebo. IMUX is one of this morning's top movers with a 25.3% gain on the news. My Take: Promising drug data is a always a good sign, but IMUX's chart is pretty lackluster. It also has a short ratio of 12.17%, so a targeted short squeeze could be contributing to this move higher. Beware of a pullback down the road. TransCode Therapeutics [RNAZ] - Last Close: $0.3306 TransCode just received a major government grant. The oncology-focused biotech announced this morning that it has been awarded the third year of a Fast-Track Small Business Innovation Research grant. The National Institute of Health grant will support the clinical evaluation of TransCode's lead therapeutic candidate, TTX-MC138. In total, the grant awarded the company nearly $871,000 to help fund further drug development. CEO Michael Dudley said the grant will help fund a first-in-human study of TTX-MC138 in patients with metastatic disease. Shares of RNAZ are up 11.6% on active premarket trading volume in response to the NIH grant. My Take: Sounds like this company has a promising drug candidate on deck. The only problem is, it could take years before a major catalyst materializes. RNAZ could be worth watching, but be patient. That's it for today! Thanks for reading, and good luck out there! Best Regards, Chris D. -- Elite Trade Club P.S... Want alerts delivered straight to your cell every morning for free?* Text ELITE to 47121 to sign up now and get our watchlists sent directly to your phone! Or text CLOSE to 47121 to get on the mobile alert list for our Closing Bell Roundup report, featuring the day's top winners and losers. *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside of these emails. 1969 S. ALAFAYA TRAIL Orlando FL 32828 USA [Unsubscribe]( | [Change Subscriber Options](